#Belimumab safety in pregnancy EudraVigilance database retrospect study 47 preg: BEL stopped 1st trimester (group A) vs. cont'd (group B) - no diff in fetal death - more preterm birth/low birth weight, congenital malform'n in group A (not stat sig) #EULAR2022 @rheumnow POS0705 https://t.co/sLQ3MHNcWa

#COVIDvaccine is effective in active and inactive #SLE disease. Noted reduced response for MMF, MTX, GC>10 mg/day. Threshold of B cells is 9+ cell/uL to have a vaccine response. Prof T Dorner #EULAR2022 @rheumnow https://t.co/qyNUZxMccD

#SLE responses with #anifrolimumab separate vs standard of care+placebo& LLDAS at 12 weeks-predictor was high Type I IFN (younger, ⬆️disease activity) but diff sig for response w #belimumab. At bedside diff to tell pts with various signatures apart. #EULAR2022 @RheumNow Dorner https://t.co/98Sb3MIEps

#OP0143 #EULAR2022 We need to screen/monitor our patients with #lupus for infection. Amsterdam cohort (>200 pts) reported association of infection and flare. 50% were on steroid. Infection type did not influence flare @RheumNow https://t.co/Pxpx5hXLv9

Another promising drug for #SLE! Monoclonal Ab to BDCA2 ; phase II study noted improvement in joint manifestation but not impressive in cutaneous dz. - Prof T Dorner #EULAR2022 @rheumnow https://t.co/eKwQyomJUD

#ClinicalPearl 2/3 of pts with #SLE have Type 1 interferon signature. So, 1/3 of #lupus is NOT driven by this pathway. Importance may be what is targeted in each pt but doesn’t necessarily predict response to #anifrolimumab #EULAR2022 @eular_org @RheumNow T Dorner SLE session https://t.co/vMOC8yGJ2V

#OP0144 #EULAR2022 Promising Digital use in monitoring disease activity for clinicians. Researchers in Amsterdam developed the first e-health #SLE T2T. High acceptance rate re: usability. Need more validation and in different languages @RheumNow https://t.co/7LravXhoJ8

#ClinicalPearl #SLE has ⬆️mortality until v advanced age and if not in remission or v low disease activity Mortality is higher. Ideas: control disease activity, prevent damage, limit prednisone. @RheumNow #EULAR2022 T Dormer Session #Lupus https://t.co/90cpsBVgAb

#OP0141 #EULAR2022 What do our #lupus patients think about Treat-to-target (T2T) and are they involved? A patient survey showed improvement in QoL as most important. They were open to T2T concept but concerned of more visits + new drugs. 61% felt they were involved @RheumNow https://t.co/rT500lhrih